stella
Atopic DermatitisAugust 2024Summary reviewed November 2026

New Eczema Injection Cut Severity Scores by 84% in Early Testing

Adults with moderate to severe eczema who didn't respond to creams saw major improvement with this new injection. The highest dose reduced eczema severity scores by 84% over 16 weeks, compared to 63% with placebo.

What the trial was testing

The trial enrolled 221 patients with atopic dermatitis. The study was sponsored by Celgene and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

84% reduction in eczema severity scores with the highest dose vs. 63% with placebo.

JAMA dermatology · 2024 · NCT04800315

These findings — that high-dose injection cut eczema severity scores 84% over 16 weeks vs. 63% for placebo — were published in the JAMA dermatology and represent the headline result of the study.

Researchers tracked outcomes across 221 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with atopic dermatitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This early-stage study shows the injection significantly improved moderate to severe eczema that wasn't controlled by creams alone. The treatment was generally well-tolerated with manageable side effects. This is not yet FDA-approved — ask your doctor about other available options or whether you might qualify for ongoing trials.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.